BACKGROUND/AIM: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs. MATERIALS AND METHODS: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease's patients treated for different solid tumors. RESULTS: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%. CONCLUSION: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
BACKGROUND/AIM: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs. MATERIALS AND METHODS: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease'spatients treated for different solid tumors. RESULTS: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%. CONCLUSION: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Authors: Ben G L Vanneste; Evert J Van Limbergen; Tom Marcelissen; Kobe Reynders; Jarno Melenhorst; Joep G H van Roermund; Ludy Lutgens Journal: Clin Transl Radiat Oncol Date: 2021-01-25
Authors: Ben G L Vanneste; Evert J Van Limbergen; Kees van de Beek; Emile van Lin; Ludy Lutgens; Philippe Lambin Journal: Tech Innov Patient Support Radiat Oncol Date: 2018-03-20